CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 125 enrolled
Drug / intervention
MGL-3196 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02912260
NCT02912260Phase 2Completed
CompareCT.gov

A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-controlled Study of MGL-3196 in Patients With Non-alcoholic Steatohepatitis

Madrigal Pharmaceuticals, Inc.·interventional·Posted Sep 23, 2016·Updated Dec 23, 2025

In Brief

A Phase 2 clinical trial evaluating MGL-3196 and Placebo for Non-alcoholic Steatohepatitis. Completed, enrolled 125 participants across 26 sites.

Detailed Summary

The primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change in hepatic fat fraction from baseline in participants with biopsy-proven Non-alcoholic Steatohepatitis (NASH).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-alcoholic Steatohepatitis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 23, 2016
Enrollment StartOct 18, 2016
Primary CompletionOct 25, 2017
Study CompletionNov 23, 2021
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 9.8 years ago

Interventions

MGL-3196drug

Placebodrug